Belyntic GmbH


Resident viruses like EBV or CMV are a threat to millions of immunocompromised people and are linked to the development of the most threatening diseases of our time, such as cancer or Alzheimer's. At Belyntic, we want to leverage the power of the human immune system, particularly the T-cell repertoire, to eradicate such unmet viral diseases. With our platform technology based on self-adjuvant peptides, we want to enable the development of prophylactic and therapeutic nanovaccines.